Overview

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Lexicon Pharmaceuticals